hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06271096, orgStudyIdInfo id: 638/ADR/KMC, briefTitle: Intramuscular Midazolam Versus Intravenous Diazepam for Acute Seizure in Children, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-11-01, primaryCompletionDateStruct date: 2022-11-01, completionDateStruct date: 2024-01-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Arooj Khan, class: OTHER, descriptionModule briefSummary: IM-midazolam in acute seizures, whenever IV cannulation is not possible. It is easy to administer and can be used in prehospital settings as IV cannulation requires experience, especially in pediatric age group. Moreover, the transit time to the hospital can be prolonged in our areas which can delay the treatment if intravenous cannulation is considered. More studies are required to assess the feasibility of administering IM-midazolam in a prehospital setting to control acute seizures, conditionsModule conditions: Seizures, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study was a randomized controlled trial carried out between November 2019 to November 2022 in the Pediatric department of Khyber Teaching Hospital. A total of 150 children who presented to the emergency department with seizures were enrolled in this study via consecutive sampling. This study was approved by the Ethical Review, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ACTUAL, armsInterventionsModule interventions name: Intra muscular Midazolam, interventions name: Intravascular Diazepam, outcomesModule primaryOutcomes measure: Fits Controlled, eligibilityModule sex: ALL, minimumAge: 3 Months, maximumAge: 5 Years, stdAges: CHILD, contactsLocationsModule locations facility: Khyber Teaching Hospital, city: Peshawar, zip: 25000, country: Pakistan, geoPoint lat: 34.008, lon: 71.57849, hasResults: False
protocolSection identificationModule nctId: NCT06271070, orgStudyIdInfo id: 2023-R23, briefTitle: Analysis of Correlation Between Skin Carotenoid Level and Basic Indicators of Health Status Related to Lifestyle in Vietnamese: An Observational Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-16, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: KAGOME CO., LTD., class: INDUSTRY, collaborators name: Dr. Binh_Teleclinic - Branch of E2E Solution Company Limited, descriptionModule briefSummary: To clarify the relationship between vegetable intake and lifestyle-related disease in Vietnam, we measure skin carotenoid levels and basic indicators of health status related to lifestyle and analyze the correlation between them. This is an important study that can lead to dietary suggestions for preventing lifestyle-related diseases in Vietnam., conditionsModule conditions: Lifestyle Risk Reduction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Non-intervention, outcomesModule primaryOutcomes measure: Skin carotenoid level, primaryOutcomes measure: Blood markers of lifestyle-related diseases, primaryOutcomes measure: BMI, primaryOutcomes measure: Body fat percentage, primaryOutcomes measure: Blood pressure, secondaryOutcomes measure: Questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dr. Binh_Teleclinic - Branch of E2E Solution Company Limited, status: RECRUITING, city: Hanoi, zip: 11612, country: Vietnam, contacts name: Nguyen Thuy Lan, Doctor, role: CONTACT, phone: +84 243 622 7799, geoPoint lat: 21.0245, lon: 105.84117, hasResults: False
protocolSection identificationModule nctId: NCT06271044, orgStudyIdInfo id: RAILESS, briefTitle: a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2014-10, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Helsinki University Central Hospital, class: OTHER, descriptionModule briefSummary: To study if its is safe to reduce the amount of postoperative treatments in those patients, who have been operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm, and in whom postoperative thyroglobulin levels are of low level., conditionsModule conditions: to Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Patients with low risk papillary thyroid cancer either received a radioiodine treatment according to the normal Finnish treatment schedule or were schedulded for only follow-up ., primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: No masking., enrollmentInfo count: 61, type: ACTUAL, armsInterventionsModule interventions name: With radioiodine treatment, interventions name: With postoperative radioiodine treatment, outcomesModule primaryOutcomes measure: Event free situation during follow-up event free /disease free, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06271031, orgStudyIdInfo id: LHS0211, briefTitle: Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infection, Sepsis and Systemic Infection, acronym: CSM-BSI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Liverpool University Hospitals NHS Foundation Trust, class: OTHER_GOV, descriptionModule briefSummary: The goal of this study is to create a computer simulation of patients with bloodstream infection to understand how changes in healthcare policies and resources affect patient treatment. This simulation will help doctors and health-care decision makers make better choices in treating these patients and avoid overusing antibiotics that can lead to antibiotic resistance. Antibiotic resistance is when bacteria can't be killed by antibiotics anymore. Participants will not receive treatments as this is an observational study, but the study will involve:* Interviews with healthcare staff to understand patient care pathways.* Analysis of historical data on bacteria causing infections and antibiotic treatments.* A 30-day observational study to observe patient treatment for bloodstream infections., conditionsModule conditions: Sepsis, conditions: Bloodstream Infection, conditions: Bacteraemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Generation of a software simulation model that is fine tuned to the observed data., secondaryOutcomes measure: Exploration of the performance of the model in different hypothesised scenarios., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_ICF, hasProtocol: True, hasSap: False, hasIcf: True, label: Study Protocol and Informed Consent Form, date: 2023-10-10, uploadDate: 2023-11-14T09:05, filename: Prot_ICF_000.pdf, size: 2058603, hasResults: False
protocolSection identificationModule nctId: NCT06271005, orgStudyIdInfo id: 000824, briefTitle: Neurological Dry Eye Study Stimulating Both Lacrimal and Vagus Nerves, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Genetic Disease Investigators, class: OTHER, descriptionModule briefSummary: This is a study on neurological dry eye disease, focusing on a patented over-the-counter supplement supporting tear production neurologically, including the lacrimal and vagus nerves., conditionsModule conditions: Dry Eye Disease, conditions: Dry Eye, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: NeuroTears, interventions name: Placebo, outcomesModule primaryOutcomes measure: OSDI, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06270992, orgStudyIdInfo id: 123R030, briefTitle: Oral Microbiome Diagnostics of Lung Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-15, primaryCompletionDateStruct date: 2025-02-15, completionDateStruct date: 2026-05-15, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: TC Erciyes University, class: OTHER, collaborators name: THE SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TÜRKİYE, descriptionModule briefSummary: The study aims to develop a deep learning-based diagnostic method for lung cancer using the oral microbiome. This innovative approach involves establishing an observational cohort of 576 individuals, including lung cancer patients, non-cancerous benign lung disease patients, and healthy controls, to collect tongue swab samples for 16S rRNA sequencing. Additionally, an international cohort of approximately 1700 individuals will be formed using in silico data. The project will utilize deep learning methods to analyze all data integratively and develop an AI diagnostic algorithm capable of distinguishing lung cancer patients from others. The diagnostic method's performance will be tested in a pilot clinical trial with 96 individuals using a PRoBE design. Led by experts in chest surgery, molecular microbiology, and bioinformatics, the project spans over 30 months and aims to create a non-invasive, easily accessible lung cancer screening method that could lead to significant diagnostic advancements and potential spin-off companies in the field of liquid biopsy/molecular diagnosis., conditionsModule conditions: Lung Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 676, type: ESTIMATED, armsInterventionsModule interventions name: NCCN (National Comprehensive Cancer Network) diagnosis, outcomesModule primaryOutcomes measure: Diagnostics accuracy assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erciyes University Hospital, status: RECRUITING, city: Kayseri, zip: 38039, country: Turkey, contacts name: Aycan Gundogdu, PhD, role: CONTACT, phone: +90 352 207 6666, email: agundogdu@erciyes.edu.tr, geoPoint lat: 38.73222, lon: 35.48528, hasResults: False
protocolSection identificationModule nctId: NCT06270966, orgStudyIdInfo id: 28287 08/11/2023, briefTitle: Cognitive Remediation VR Tool for People With MCI: a Feasibility RCT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-07, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: University of Cagliari, class: OTHER, descriptionModule briefSummary: The need to promote research in active aging trough multidisciplinary and innovative approaches is strongly indicated by the European Union. Our study aims to assess the feasibility and provide a preliminary measure of effectiveness for an intervention using immersive virtual reality (VR) technology for cognitive remediation (CR) in individuals with Mild Cognitive Impairment (MCI), conditionsModule conditions: Mild Cognitive Impairment, conditions: Cognitive Remediation, conditions: Virtual Reality, conditions: Psychiatric Rehabilitation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized Controlled Trial, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Virtual Reality Cognitive Remediation, outcomesModule primaryOutcomes measure: Side effects; Dropout rates; Proportion of recruited participants among those considered eligible, secondaryOutcomes measure: Short Form Health Survey, 12 items (SF-12), secondaryOutcomes measure: Brief Social Rhythms Scale (BSRS), secondaryOutcomes measure: Patient Health Questionnaire (PHQ-9), secondaryOutcomes measure: Generalized Anxiety Disorder-7 item (GAD-7), secondaryOutcomes measure: Addenbrooke's Cognitive Examination (ACE-R), secondaryOutcomes measure: Matrix test, secondaryOutcomes measure: Rey's Word Test, secondaryOutcomes measure: Trail Making Test (TMT), secondaryOutcomes measure: Digit Span, secondaryOutcomes measure: Stroop Test, secondaryOutcomes measure: Frontal Assessment Battery (FAB), secondaryOutcomes measure: Cognitive Estimates Test (CET), secondaryOutcomes measure: Rey Figure Test, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: San Giovanni di Dio Hospital, city: Cagliari, state: CA, zip: 09100, country: Italy, geoPoint lat: 39.23054, lon: 9.11917, hasResults: False
protocolSection identificationModule nctId: NCT06270953, orgStudyIdInfo id: DZ_NX_US, briefTitle: Non-invasive Monitoring: Impact on Patient Management and Outcomes, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-19, primaryCompletionDateStruct date: 2024-03-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Turtle Shell Technologies Pvt. Ltd., class: INDUSTRY, descriptionModule briefSummary: Enhancing patient monitoring in SNFs and ALFs is crucial due to challenges in recognizing deteriorating health. Gaps in vital sign checks lead to missed indicators and adverse outcomes. Turtle Shell Technologies' Dozee Pro NX offers continuous non-invasive monitoring, alerting healthcare providers of vital sign changes. This clinical study aims to evaluate Dozee Pro Nx's impact on patient outcomes, practitioner efficiency, and healthcare costs in SNFs and ALFs, addressing gaps in care delivery., conditionsModule conditions: No Specific Medical Conditions or Disease States, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Dozee Pro NX, outcomesModule primaryOutcomes measure: Number of Care Escalation and/or Transfers (Subgroup- ER visits, Surgical Interventions & Hospitalizations, ICU Admissions),, secondaryOutcomes measure: HCP experience response data, secondaryOutcomes measure: Care pathway mapping, eligibilityModule sex: ALL, minimumAge: 18 Months, maximumAge: 120 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Oak Village Healthcare, status: RECRUITING, city: Lake Jackson, state: Texas, zip: 77566, country: United States, contacts name: Lindsay Darthard, LNFA, role: CONTACT, phone: 979-319-2306, email: lindsaydarthard@gcltc.com, contacts name: Lindsay Darthard, LNFA, role: PRINCIPAL_INVESTIGATOR, contacts name: Marc A Wilson, MD, role: SUB_INVESTIGATOR, geoPoint lat: 29.03386, lon: -95.43439, hasResults: False
protocolSection identificationModule nctId: NCT06270927, orgStudyIdInfo id: 00003830, briefTitle: A Feasibility Study for Randomization of Code Stroke Imaging Strategies, acronym: CSI, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-23, primaryCompletionDateStruct date: 2024-03-30, completionDateStruct date: 2024-07-10, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: University of Texas at Austin, class: OTHER, collaborators name: Lone Star Stroke Research Consortium, descriptionModule briefSummary: The purpose of this study is to test feasibility of a comparative effectiveness framework for acute stroke imaging using prospective electronic health data. This is a prospective, cohort feasibility study of patients presenting to the Emergency Department with suspected acute ischemic stroke. The clinical stroke team will not be blinded to the imaging modality given the nature and purpose of the interventions/imaging. Knowledge of the imaging modality used and the knowledge gained from the resulting data will need to be considered for treatment decisions. Blinding will be maintained for data abstraction and analyses. Analysis will be on an "intent-to-scan" basis and all qualifying patients will be included in their assigned cohort., conditionsModule conditions: Brain Ischemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: MRI, interventions name: CT, outcomesModule primaryOutcomes measure: compliance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ascension Seton, status: RECRUITING, city: Austin, state: Texas, zip: 78712, country: United States, contacts name: Adrienne N Dula, PhD, role: CONTACT, phone: 512-495-5922, email: adrienne.dula@austin.utexas.edu, contacts name: Karinne Berstis, MA, role: CONTACT, email: karinne@austin.utexas.edu, geoPoint lat: 30.26715, lon: -97.74306, hasResults: False
protocolSection identificationModule nctId: NCT06270888, orgStudyIdInfo id: IRB23-1011, briefTitle: Hypofractionation (Radiation) Trial for Multiple Myeloma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-05-01, completionDateStruct date: 2028-05-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: University of Chicago, class: OTHER, descriptionModule briefSummary: This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiation therapy. Doctors leading this study would like to see if a shorter radiation course (i.e., hypofractionation) for pelvic radiation is safe for multiple myeloma. Because participants in this study will receive a shortened radiation course, each daily treatment dose that is delivered would be slightly higher than normal. This higher daily dose would be delivered because the study team would like to see if higher doses of radiation are as safe given over a shorter number of days compared to 2-3 weeks. The purpose of this study is to make sure that hypofractionation is safe and effective for individuals with multiple myeloma., conditionsModule conditions: Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Radiation, outcomesModule primaryOutcomes measure: Maximum Tolerated Dose of Radiation of Per Fraction, secondaryOutcomes measure: Rate of Grade 3 or Higher Adverse Events, secondaryOutcomes measure: Rate of Long-Term Adverse Events, secondaryOutcomes measure: Overall Response Rate, secondaryOutcomes measure: Progression-free Survival, secondaryOutcomes measure: Local Control of the treated Lesion, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The University of Chicago Comprehensive Cancer Center, city: Chicago, state: Illinois, zip: 60637, country: United States, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06270849, orgStudyIdInfo id: MTU-EC-SU-0-002/66, briefTitle: Validity and Reliability of ICIQ-FLUTS LF in Thai Version and Correlation With IPSS, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-24, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2024-01-20, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Thammasat University Hospital, class: OTHER, descriptionModule briefSummary: The investigators recruited participants, who were female with LUTS 50 participants for known group validity and 80 normal control females to evaluate for construct validity and test for reliability by statistical analysis., conditionsModule conditions: Validity of Thai Version of the ICIQ-FLUTS LF Questionnaire, conditions: Reliability of Thai Version of the ICIQ-FLUTS LF, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 130, type: ACTUAL, armsInterventionsModule interventions name: Questionnaire, outcomesModule primaryOutcomes measure: How well the ICIQ-FLUTS LF questionnaire in the Thai version can differentiate between females with LUTS and normal females, was assessed by the construction validity., primaryOutcomes measure: The correlation between items within a subscale of the ICIQ-FLUTS LF questionnaire assessed by internal consistency., primaryOutcomes measure: The consistency of the repeated measurements by the Thai version of the ICIQ-FLUTS LF was assessed by the test-retest reliability., secondaryOutcomes measure: The correlation between the IPSS questionnaire and ICIQ-FLUTS LF questionnaire was assessed by convergent validity., eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Thammasat University Hospital, city: Khlong Luang, state: Pathumthani, zip: 12120, country: Thailand, geoPoint lat: 14.06467, lon: 100.64578, hasResults: False